Single Nucleotide Variation in the Promoter Region of the APOA1 Gene as a Candidate Biomarker for Dyslipidemia
Downloads
Dyslipidemia is a lipid profile abnormality that can escalate the risk of cardiovascular disease. The rate of cardiovascular events in Indonesia is very high. One of the causes of dyslipidemia is due to polymorphisms in genes associated with lipid metabolism. The APOA-1 gene encodes the APOA-1 protein which functions to regulate HDL protein synthesis. The objective of this study is to determine APOA1 gene polymorphisms in patients with dyslipidemia. Samples of healthy controls and dyslipidemia patients were used in this investigation. The lipid profiles of the patients and normal controls are determined at the onset of the study. Following DNA extraction, the APOA-1 gene was amplified and sequenced using the serum sample. MEGA X and BLAST were used to analyze the sequencing results. The study's findings demonstrated that the APOA-1 gene length in samples of dyslipidemic patients and normal controls was 433 bp. While the normal control samples have the same sequence as the database, the dyslipidemic patient samples have an APOA-1 gene polymorphism in the promoter region. APOA-1 gene polymorphism results in disturbances in lipid profiles, particularly HDL which is at risk of developing dyslipidemia. The APOA-1 gene has the potential to be developed as a biomarker for diagnosing dyslipidemia involving a larger number of samples.
Al-bustan, S. A., Al-serri, A. E., Annice, B. G., Alnaqeeb, M. A., & Ebrahim, G. A. (2013). Re-sequencing of the APOAI promoter region and the genetic association of the -75G > A polymorphism with increased cholesterol and low density lipoprotein levels among a sample of the Kuwaiti population. BMC Medical Genetics, 14(1), 1. https://doi.org/10.1186/1471-2350-14-90
Asif, S., Khan, M., Waqar Arshad, M., & Shabbir, M. I. (2021). PCR Optimization for Beginners: A Step by Step Guide. Research in Molecular Medicine, 9(2), 81–102. https://doi.org/10.32598/rmm.9.2.1189.1
Asselbergs, F. W., Guo, Y., Van Iperen, E. P. A., Sivapalaratnam, S., Tragante, V., Lanktree, M. B., … Drenos, F. (2012). Large-Scale Gene-Centric Meta-analysis Across 32 Studies Identifies Multiple Lipid Loci. American Journal of Human Genetics, 91(5), 823–838. https://doi.org/10.1016/j.ajhg.2012.08.032
de Grooth, G. J., Klerkx, A. H. E. ., Stroes, E. S. G., Stalenhoef, A. F. H., Kastelein, J. J. P., & Kuivenhoven, J. A. (2004). A review of CETP and its relation to atherosclerosis. Journal Lipid Research, 45(11), 1967–1974. https://doi.org/10.1194/jlr.R400007-JLR200
Eldeeb, M. A., Zaki, A. S., Ashour, S., Abdel Nasser, A., El Bassiouny, A., & Abdulghani, K. O. (2020). Serum Apolipoprotein A1: a Predictor and Prognostic Biomarker in Acute Ischemic Stroke. Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 56(3). https://doi.org/10.1186/s41983-019-0138-z
Fan, L., You, Y., Fan, Y., Shen, C., & Xue, Y. (2021). Association Between ApoA1 Gene Polymorphisms and Antipsychotic Drug-Induced Dyslipidemia in Schizophrenia. Neuropsychiatric Disease and Treatment, 17, 1289–1297. https://doi.org/10.2147/NDT.S305200
França, E. De, Alves, J. G. ., & Hutz, M. . (2005). APOA1 / C3 / A4 gene cluster variability and lipid levels in Brazilian children. Brazillian Journal of Medical and Biological Research, 38(4), 535–541. https://doi.org/10.1590/S0100-879X2005000400006
García-Giustiniani, D., & Stein, R. (2016). Genetics of dyslipidemia. Arquivos Brasileiros de Cardiologia, 106(5), 434–438. https://doi.org/10.5935/abc.20160074
Gene, M., Bora, K., Saikia, M., Borah, P., Hussain, I., & Das, D. (2016). Single nucleotide polymorphisms of APOA1 gene and their relationship with serum apolipoprotein A-I concentrations in the native population of Assam. Meta Gene, 7, 20–27. https://doi.org/10.1016/j.mgene.2015.10.005
Georgila, K., Vyrla, D., & Drakos, E. (2019). Apolipoprotein A-I (ApoA-I), Immunity, Inflammation and Cancer. Cancers, 11(8), 1–26. https://doi.org/10.3390/cancers11081097
Haase, C. L., Tybjærg-hansen, A., Grande, P., & Frikke-schmidt, R. (2010). Genetically Elevated Apolipoprotein A-I, High-Density Lipoprotein Cholesterol Levels, and Risk of Ischemic Heart Disease. J Clin Endocrinol Metab, 95(12), 500–510. https://doi.org/10.1210/jc.2010-0450
Hedayatnia, M., Asadi, Z., Zare-feyzabadi, R., Yaghooti-khorasani, M., Ghazizadeh, H., Ghaffarian-zirak, R., … Ghayour-mobarhan, M. (2020). Dyslipidemia and cardiovascular disease risk among the MASHAD study population. Lipids in Health and Disease, 19(42), 1–11. https://doi.org/10.1186/s12944-020-01204-y
Hsu, L., & Lee, T. (2017). ScienceDirect Apolipoprotein A1 rs5070 A / G polymorphism with stroke subtypes in Taiwan. Journal of the Chinese Medical Association, 80(6), 360–365. https://doi.org/10.1016/j.jcma.2017.01.002
Jian, Z., Lung, C., Ko, P., Sun, Y., Huang, J., Ho, C., … Liaw, Y. (2013). The association between the apolipoprotein A1 / high density lipoprotein -cholesterol and diabetes in Taiwan — a cross-sectional study. BMC Endocrine Disorder, 13(42), 1–8. https://doi.org/10.1186/1472-6823-13-42
Kementerian Kesehatan Republik Indonesia. (2018). Hasil Riset Kesehatan Dasar Tahun 2018. Kementerian Kesehatan Republik Indonesia.
Kopin, L., & Lowenstein, C. (2017). In the Clinic Dyslipidemia. Annals of Internal Medicine, 167(11), ITC81–ITC95. https://doi.org/10.7326/AITC201712050
Liao, B. H., Cheng, K. Q., Dong, S. H., Liu, H. D., & Xu, Z. L. (2015). Effect of apolipoprotein A1 genetic polymorphisms on lipid profiles and the risk of coronary artery disease. Diagnostic Pathology, 10(1), 1–5. https://doi.org/10.1186/s13000-015-0328-7
Liu, S., Liu, J., Weng, R., Gu, X., & Zhong, Z. (2019). Apolipoprotein E gene polymorphism and the risk of cardiovascular disease and type 2 diabetes. BMC Cardiovascular Disorders, 19(213), 1–6. https://doi.org/10.1186/s12872-019-1194-0
Liu, T. N., Wu, C. T., He, F., Yuan, W., Li, S. X., Li, H. W., … Wu, M. (2016). Relationship between the G75A polymorphism in the apolipoprotein A1 (ApoA1) gene and the lipid regulatory effects of pravastatin in patients with hyperlipidemia. Genetics and Molecular Research, 15(2). https://doi.org/10.4238/gmr.15028216
Pagani, F., Sidoli, A., Giudici, G. A., Barenghi, L., Vergani, C., & Baralle, F. E. (1990). Human apolipoprotein A-I gene promoter polymorphism : association with hyperalp ha1 i poproteinemia. Journal Lipid Research, 31(8), 1371–1377. https://doi.org/10.1016/S0022-2275(20)42608-2
Pakdel, A., Reza, M., Eidgahi, A., & Bandegi, A. R. (2018). Association Between MspI Polymorphisms of the Apolipoprotein A-I Gene and Hyperlipidemia in an Iranian Population. Middle East J Rehabil Helath Stud, 5(1), 26–29. https://doi.org/10.5812/mejrh.60496.Research
Pandith, A. A., Bhat, I. A., Niyaz, I., Qasim, I., Bhat, I. A., Manzoor, U., & Koul, A. M. (2021). Association of APOA1-75G/A and+ 83C/T polymorphic variation with acute coronary syndrome patients in Kashmir (India). Journal of Cardiovascular and Thoracic Research, 13(2), 109.–115. https://doi.org/10.34172/jcvtr.2021.09
Rashad, N. M., Ebrahem, G. A., El-shal, A. S., Zenar, M. R. H. A.-, Ahmed, I. G., & Hamed, M. G. (2021). Association of Apolipoprotein A1 Gene Polymorphism and Coronary Heart Diseases in Patients with Type 2 Diabetes Mellitus. The Eguptian Journal of Hospital Medicine, 82(2), 289–295. https://doi.org/10.21608/ejhm.2021.143897
Rojas, M. P., Prieto, C., Bermúdez, V., Garicano, C., Nava, T. N., Martínez, M. S., ... & Rojas, J. (2017). Dyslipidemia: Genetics, lipoprotein lipase and HindIII polymorphism. F1000Research, 6. https://doi.org/10.12688/f1000research.12938.1
Shioji, K., Mannami, Æ. T., Kokubo, Æ. Y., Goto, Y., Nonogi, H., & Iwai, N. (2004). An association analysis between ApoA1 polymorphisms and the high-density lipoprotein ( HDL ) cholesterol level and myocardial infarction ( MI ) in Japanese. J Hum Genet, 49, 433–439. https://doi.org/10.1007/s10038-004-0172-1
Smach, M. A., Edziri, H., Charfeddine, B., Othman, L. Ben, Lammouchi, T., Ltaief, A., … Limem, K. (2012). Polymorphism in apoA1 Influences High-Density Lipoprotein Cholesterol Levels but Is Not a Major Risk Factor of Alzheimer ’ s Disease. Dement Geriatr Cogn Disord Extra, 1, 249–257. https://doi.org/10.1159/000329910
Smith, J. D., Brinton, E. A., & Breslow, J. L. (1992). Polymorphism in the human apolipoprotein AI gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. The Journal of clinical investigation, 89(6), 1796-1800. https://doi.org/ 10.1172/JCI115783
Stover, N. A., & Cavalcanti, A. R. O. (2017). Using NCBI BLAST. Current Protocols in Essential Laboratory Techniques, 2017(May), 11.1.1-11.1.34. https://doi.org/10.1002/cpet.8
Urry, L. A., Meyers, N., Cain, M. L., Wasserman, S. A., Minorsky, P. V., Orr, R., ... & Campbell, N. A. (2021). Campbell biology: Australian and New Zealand version. Pearson Australia.
Wang, Yanmei, Lu, Z., Zhang, J., Yang, Y., Shen, J., Zhang, X., & Song, Y. (2016). The APOA5 rs662799 polymorphism is associated with dyslipidemia and the severity of coronary heart disease in Chinese women. Lipids in Health and Disease, 15(170), 1–9. https://doi.org/10.1186/s12944-016-0343-z
Wang, Yanzhe, Liu, F., Li, L., Deng, S., & He, Z. (2017). The association between apolipoprotein A1-C3-A5 gene cluster promoter polymorphisms and risk of ischemic stroke in the northern Chinese Han population. Journal of International Medical Research, 45(6), 2042–2052. https://doi.org/10.1177/0300060517713517
Westfall, P. J., Pitera, D. J., Lenihan, J. R., Eng, D., Woolard, F. X., & Regentin, R. (2012). Production of amorphadiene in yeast , and its conversion to dihydroartemisinic acid , precursor to the antimalarial agent artemisinin. PNAS, 109(3), 111–118. https://doi.org/10.1073/pnas.1110740109
WHO. (2019). WHO Updates Cardiovascular Risk Charts. WHO
Xu, L., Zhou, Y., Yao, J., Sun, S., Rui, Q., Yang, X., & Li, X. (2017). Apolipoprotein A1 polymorphisms and risk of coronary artery disease : a meta-analysis. Arch Med Sci, 4, 813–819.
Xu, X., Song, Z., Mao, B., & Xu, G. (2022). Review Article Apolipoprotein A1-Related Proteins and Reverse Cholesterol Transport in Antiatherosclerosis Therapy : Recent Progress and Future Perspectives. Cardiovascular Therapeutics. https://doi.org/10.1155/2022/4610834
Copyright (c) 2023 JURNAL INFO KESEHATAN
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright notice
Ownership of copyright
The copyright in this website and the material on this website (including without limitation the text, computer code, artwork, photographs, images, music, audio material, video material and audio-visual material on this website) is owned by JURNAL INFO KESEHATAN and its licensors.
Copyright license
JURNAL INFO KESEHATAN grants to you a worldwide non-exclusive royalty-free revocable license to:
- view this website and the material on this website on a computer or mobile device via a web browser;
- copy and store this website and the material on this website in your web browser cache memory; and
- print pages from this website for your use.
- All articles published by JURNAL INFO KESEHATAN are licensed under the Creative Commons Attribution 4.0 International License. This permits anyone to copy, redistribute, remix, transmit and adapt the work provided the original work and source is appropriately cited.
JURNAL INFO KESEHATAN does not grant you any other rights in relation to this website or the material on this website. In other words, all other rights are reserved.
For the avoidance of doubt, you must not adapt, edit, change, transform, publish, republish, distribute, redistribute, broadcast, rebroadcast or show or play in public this website or the material on this website (in any form or media) without appropriately and conspicuously citing the original work and source or JURNAL INFO KESEHATAN prior written permission.
Permissions
You may request permission to use the copyright materials on this website by writing to jurnalinfokesehatan@gmail.com.
Enforcement of copyright
JURNAL INFO KESEHATAN takes the protection of its copyright very seriously.
If JURNAL INFO KESEHATAN discovers that you have used its copyright materials in contravention of the license above, JURNAL INFO KESEHATAN may bring legal proceedings against you seeking monetary damages and an injunction to stop you using those materials. You could also be ordered to pay legal costs.
If you become aware of any use of JURNAL INFO KESEHATAN copyright materials that contravenes or may contravene the license above, please report this by email to jurnalinfokesehatan@gmail.com
Infringing material
If you become aware of any material on the website that you believe infringes your or any other person's copyright, please report this by email to jurnalinfokesehatan@gmail.com.
